In the chain of early diagnosis and treatment of breast cancer, breast biopsy is a crucial link that bridges the gap between imaging screening and pathological diagnosis. It bridges the "suspicions" identified by imaging screening and leads to the "definitive evidence" of pathological diagnosis. The breast biopsy needle is the core tool that accomplishes this transition. Its clinical application has expanded from simple sampling diagnosis to therapeutic resection, efficacy assessment, and even molecular pathological research, providing comprehensive support for the precise management of breast diseases.

Core Diagnostic Scenario: From Suspicious Lumps to Hidden Lesions

Evaluation of palpable masses: For breast masses detected by patients' self-examination or doctors' palpation, ultrasound-guided hollow needle biopsy (CNB) or vacuum-assisted biopsy (VABB) are the preferred methods for pathological diagnosis. It can clearly determine the benign or malignant nature of the mass and avoid unnecessary surgical trauma.

Localization and sampling of microcalcification foci: Clustered microcalcifications detected by mammography are important signs of early breast cancer, especially ductal carcinoma in situ (DCIS). These calcification points are usually not palpable. The VABB technique guided by stereotactic positioning plays a significant role. The system calculates the three-dimensional coordinates of the calcification foci through a computer and guides the biopsy needle for precise rotary sampling to obtain tissue containing calcification, with an extremely high diagnostic rate.

Differentiation between complex cysts and solid nodules: The mixed echogenic lesions with cystic and solid components shown under ultrasound have an unclear nature. Fine needle aspiration (FNAB) can quickly aspirate the cyst fluid for cytological examination, while CNB or VABB can sample the solid part to achieve accurate differentiation.

Evaluation of nipple discharge: For unilateral, single-hole bloody or serous nipple discharge, it often indicates the presence of a lesion in the ducts. Biopsy under ductoscopy or targeted puncture of the dilated ducts can locate and obtain epithelial cells or tissues from the diseased duct.

Monitoring the efficacy of neoadjuvant therapy: For locally advanced breast cancer, preoperative neoadjuvant chemotherapy or targeted therapy has become a standard procedure. In the middle of the treatment, CNB or VABB can be performed again on the original lesion for biopsy. Through pathological assessment (such as Miller-Payne grading) and changes in molecular markers, the tumor's response to treatment can be evaluated in real time, providing a basis for adjusting subsequent treatment strategies.

Beyond Diagnosis: The Therapeutic and Research Value of Biopsy Needles

Modern breast biopsy needles, especially the VABB system, have clear therapeutic functions. For small tumors with a high possibility of being benign as determined by imaging (such as fibroadenomas), patients who wish can directly undergo minimally invasive rotary resection for complete removal using the VABB. The surgery leaves only a puncture point scar approximately 3-5 millimeters in size, meeting the patients' dual needs for aesthetics and minimality. The Revolve™ ST system of TAVICOM, among others, is specifically designed for such diagnostic resection surgeries.

More importantly, the tissues obtained through biopsy are valuable materials for molecular typing and genetic testing. Through immunohistochemical detection of biopsy samples (ER, PR, HER2, Ki-67), the molecular subtypes of breast cancer (Luminal A/B type, HER2 overexpression type, triple-negative type) can be determined. This is the fundamental basis for formulating personalized treatment plans (endocrine therapy, targeted therapy, chemotherapy). Furthermore, using biopsy tissues for multi-gene testing (such as Oncotype DX, MammaPrint) can assess the risk of recurrence and guide whether chemotherapy is needed, achieving true "precision medicine".

Integration of Guiding Technologies: Making the Needle Tip "Possess Eyes"

The precise application of biopsy needles is inseparable from the rapid development of imaging guidance technology. Ultrasound guidance is real-time and non-radiative, making it the preferred choice for most accessible or ultrasound-visible lesions. Mammography stereotactic positioning is the gold standard for diagnosing hidden microcalcifications. While magnetic resonance (MRI) guidance targets lesions that are only visible on MRI, although the technology is complex and costly, it is crucial for screening high-risk populations. The latest technological trend is to integrate multiple imaging methods (such as ultrasound and MRI) for navigation, achieving complementary advantages and enhancing the puncture accuracy to the millimeter level.

Clinical practice has set higher requirements for the performance of biopsy needles: adequate sampling (to avoid underestimation), ease of operation (to shorten the learning curve), patient comfort (to reduce pain and anxiety), and cost-effectiveness. Manufacturers such as Hologic (with their Mammotome system) and BD (with their Vacora® system) have been continuously optimizing product designs, for instance, by using thinner needle diameters, faster sampling speeds, and more intelligent sample management systems, all aimed at better meeting these clinical needs.

In summary, the breast biopsy needle has evolved from a simple sampling tool into a multifunctional platform that integrates precise diagnosis, minimally invasive treatment, efficacy evaluation, and scientific research analysis. It serves as a bridge connecting imaging suspicion and pathological confirmation, and is an indispensable tool for implementing precise medical care for breast diseases.